Abpro (ABP) Competitors $0.24 -0.02 (-6.17%) As of 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ABP vs. CNTX, CVM, IGMS, UNCY, INCR, ASRT, PMVP, OSTX, APLT, and ELYMShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include Context Therapeutics (CNTX), CEL-SCI (CVM), IGM Biosciences (IGMS), Unicycive Therapeutics (UNCY), InterCure (INCR), Assertio (ASRT), PMV Pharmaceuticals (PMVP), OS Therapies (OSTX), Applied Therapeutics (APLT), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Its Competitors Context Therapeutics CEL-SCI IGM Biosciences Unicycive Therapeutics InterCure Assertio PMV Pharmaceuticals OS Therapies Applied Therapeutics Eliem Therapeutics Context Therapeutics (NASDAQ:CNTX) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Does the media prefer CNTX or ABP? In the previous week, Context Therapeutics had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for Context Therapeutics and 0 mentions for Abpro. Context Therapeutics' average media sentiment score of 1.11 beat Abpro's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Context Therapeutics Positive Abpro Neutral Do analysts prefer CNTX or ABP? Context Therapeutics currently has a consensus target price of $5.25, indicating a potential upside of 527.24%. Abpro has a consensus target price of $4.00, indicating a potential upside of 1,565.28%. Given Abpro's higher probable upside, analysts plainly believe Abpro is more favorable than Context Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CNTX or ABP more profitable? Abpro's return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -38.80% -37.53% Abpro N/A N/A -241.16% Do institutionals and insiders have more ownership in CNTX or ABP? 14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Abpro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, CNTX or ABP? Context Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Abpro has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Which has preferable earnings and valuation, CNTX or ABP? Abpro has higher revenue and earnings than Context Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$26.73M-$0.36-2.33Abpro$180K106.98-$7.23MN/AN/A SummaryContext Therapeutics beats Abpro on 7 of the 13 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.26M$3.12B$5.76B$9.90BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.0283.0226.61Price / Sales106.98379.66502.90163.15Price / CashN/A43.5325.7028.92Price / Book-1.148.1110.796.52Net Income-$7.23M-$53.35M$3.29B$266.21M7 Day Performance-1.44%0.01%0.13%-0.77%1 Month Performance0.46%7.04%7.22%3.84%1 Year PerformanceN/A11.96%50.16%24.37% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.24-6.2%$4.00+1,565.3%N/A$19.26M$180K0.0015Gap DownCNTXContext Therapeutics3.1912 of 5 stars$0.90+2.8%$5.25+485.3%-65.6%$78.30MN/A-2.397Positive NewsCVMCEL-SCI0.4026 of 5 stars$11.30+7.0%N/A-63.1%$77.77MN/A-23.5443Short Interest ↑Gap UpIGMSIGM Biosciences4.2481 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190Positive NewsUNCYUnicycive Therapeutics3.2951 of 5 stars$4.24-1.3%$60.00+1,316.8%+34.9%$75.77MN/A-1.039INCRInterCure0.2306 of 5 stars$1.66-0.3%N/A-23.3%$75.65M$238.85M0.00350Positive NewsASRTAssertio2.0888 of 5 stars$0.78-0.7%$2.38+204.5%-27.0%$75.61M$124.96M-1.7420PMVPPMV Pharmaceuticals2.7985 of 5 stars$1.44+1.4%$5.50+281.9%-1.9%$75.25MN/A-0.9250High Trading VolumeOSTXOS Therapies2.1271 of 5 stars$2.33+6.4%$18.00+672.5%-47.0%$74.31MN/A-2.95N/ANews CoverageAnalyst ForecastAPLTApplied Therapeutics4.1338 of 5 stars$0.53+2.0%$6.10+1,061.9%-91.3%$74.09M$460K-1.1930Positive NewsELYMEliem TherapeuticsN/A$2.48+4.2%N/A-67.3%$73.79MN/A-4.689High Trading Volume Related Companies and Tools Related Companies CNTX Alternatives CVM Alternatives IGMS Alternatives UNCY Alternatives INCR Alternatives ASRT Alternatives PMVP Alternatives OSTX Alternatives APLT Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABP Stock Alerts